A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/25/2004	WO2004100880A2 Controlled release formulation of erythromycin derivatives
11/25/2004	WO2004100876A2 The aerosolization of cromolyn sodium using a capillary aerosol generator
11/25/2004	WO2004100875A2 Benzimidazoles, compositions containing such compounds and methods of use
11/25/2004	WO2004100874A2 Androgen receptor modulators and methods of use thereof
11/25/2004	WO2004100873A2 Compounds, compositions, and methods
11/25/2004	WO2004100871A2 Combination of an aldosterone receptor antagonist and a renin inhibitor
11/25/2004	WO2004100868A2 Method of treating transplant rejection
11/25/2004	WO2004100867A2 Method and kit for regulation of microvascular tone
11/25/2004	WO2004100866A2 Alcohol-free transdermal analgesic composition
11/25/2004	WO2004100865A2 New benzimidazole derivatives
11/25/2004	WO2004100864A2 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases
11/25/2004	WO2004100863A2 Composition for preventing and treatment of asthma comprising alpha-lipoic acid as an effective component
11/25/2004	WO2004100860A2 Stable liposomes for microencapsulation of animal venoms
11/25/2004	WO2004100826A2 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/25/2004	WO2004100685A1 Mold inhibitor integrated within a matrix and method of making same
11/25/2004	WO2004100682A1 A novel composition of complex metal salt of garcinia acid, a process for preparing the same and use thereof
11/25/2004	WO2004100681A1 Method for producing a chitosan containing salt having a function of lowering blood pressure
11/25/2004	WO2004091627A3 Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
11/25/2004	WO2004091591A3 Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
11/25/2004	WO2004089942A3 Benzimidazolidinone derivatives as muscarinic agents
11/25/2004	WO2004089356A3 Targeted bone marrow protection agents
11/25/2004	WO2004089239A3 Topical anthelmintic veterinary formulations
11/25/2004	WO2004088276A3 A method and kit for detecting the early onset of renal tubular cell injury
11/25/2004	WO2004087173A3 Formulations for mediating inflammation and for reducing blood cholesterol
11/25/2004	WO2004087170B1 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease
11/25/2004	WO2004087167A3 Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
11/25/2004	WO2004084907A3 ACTIVATION SPECIFIC INHIBITORS OF NF-kB AND METHOD OF TREATING INFLAMMATORY PROCESSES IN CARDIO-VASCULAR DISEASES
11/25/2004	WO2004083174A3 Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
11/25/2004	WO2004082681B1 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases
11/25/2004	WO2004080959A3 Process for the preparation of dexmethylphenidate hydrochloride
11/25/2004	WO2004078123A3 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
11/25/2004	WO2004073637A3 Compositions comprising a defined polysaccharide component
11/25/2004	WO2004073611A3 Compounds for the treatment of metabolic disorders
11/25/2004	WO2004073610A3 Estrogen receptor modulators
11/25/2004	WO2004073607A3 Use of steroids to treat ocular disorders
11/25/2004	WO2004072255A3 Methods of treating disease
11/25/2004	WO2004071433A3 Methods of treating disease
11/25/2004	WO2004071416B1 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/25/2004	WO2004070057A3 Use of a novel polymorphism in the hsgk1 gene in the diagnosis of hypertonia and use of the sgk gene family in the diagnosis and therapy of the long qt syndrome
11/25/2004	WO2004069286A3 Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof
11/25/2004	WO2004069255A3 Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reduxtase; screening assay for the identification of novel therapeutics and their cellular targets
11/25/2004	WO2004069149A3 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
11/25/2004	WO2004069133A3 N-monoacylated o-phenylenediamines as anti -cancer agents
11/25/2004	WO2004067002A3 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
11/25/2004	WO2004064781A3 Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs
11/25/2004	WO2004064753A3 Use of n-desmethylclozapine to treat human neuropsychiatric disease
11/25/2004	WO2004064738A3 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
11/25/2004	WO2004062629A3 Apoptolidin analogs and derivatives for inducing apoptosis in transformed cells
11/25/2004	WO2004062620A3 Paricalcitol as a chemotherapeutic agent
11/25/2004	WO2004062606A3 Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
11/25/2004	WO2004060907A3 Compounds that bind p2y2 or p2y1 receptors
11/25/2004	WO2004060489A3 Treatment of chronic heart failure
11/25/2004	WO2004060378A3 Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof
11/25/2004	WO2004058151A3 Wound and skin care compositions
11/25/2004	WO2004058048A3 Dehydroepiandrosterone (dhea) congeners for prevention and/or treatment of ulcers
11/25/2004	WO2004047755A3 Fused bicyclic nitrogen-containing heterocycles
11/25/2004	WO2004034977A3 Orally administered peptides synergize statin activity
11/25/2004	WO2004034972A3 Compounds, compositions, and methods
11/25/2004	WO2004021984A3 Heterocyclic aromatic compounds useful as growth hormone secretagogues
11/25/2004	WO2004018386A3 Acetophenone potentiators of metabotropic glutamate receptors
11/25/2004	WO2004004683A8 Solid dispersions comprising two different polymer matrixes
11/25/2004	WO2003101276A3 Protective effects of pde-5 inhibitors
11/25/2004	WO2003086280A3 Immunostimulatory g,u-containing oligoribonucleotides
11/25/2004	WO2003078578A3 Modulation of the immune response through the manipulation of arginine levels
11/25/2004	US20040236416 Increased biocompatibility of implantable medical devices
11/25/2004	US20040236238 Implantable method to regulate blood pressure by means of coded nerve signals
11/25/2004	US20040236153 Novel vasoconstrictor cannabinoid analogs
11/25/2004	US20040236147 Integrin antagonist; antiinflammatory agents; antiarthritic agents; inflammatory bowel disease; lupus; multiple sclerosis; asthma; psoriasis;antidiabetic agents; cardiovascular disorders
11/25/2004	US20040236137 A carbonyloxycyano compound; pesticides; veterinary medicine
11/25/2004	US20040236125 Mixture with salicylic or arylalkanoic acid, or salt thereof, and phosphonate compound
11/25/2004	US20040236123 Flavanoid dimers or trimers, formed by oligomerization, then etherifying, esterifying or glycosylating to obtain drugs used as anticarcinogenic agents
11/25/2004	US20040236116 Novel bicyclic and tricyclic cannabinoids
11/25/2004	US20040236112 Hepatitis C Virus (HCV); antiproliferative agents; replication-defective
11/25/2004	US20040236111 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
11/25/2004	US20040236109 Tetrahydroquinoline derivatives
11/25/2004	US20040236108 Bicarbocyclic hydrazine/hydrazide compounds as inhibitors of semicarbazide-sensitive amine oxidases (SSAO); treat an inflammatory disease or condition, related to carbohydrate metabolism, smooth muscle cell function; chemical synthesis
11/25/2004	US20040236105 Triazole derivatives useful in therapy
11/25/2004	US20040236104 Substituted 4-aminocyclohexanols
11/25/2004	US20040236102 Enzyme inhibitor for treating a non-insulin dependent diabetes mellitus; 3-Amino-4-(3,4-difluorophenyl)butanoyl]-4-[2-({3-[(methylsulfonyl)amino]-phenyl}-amino)-2-oxoethyl]piperazin-2-yl}acetic acid
11/25/2004	US20040236101 Heteroindanes a new class of potent cannabimimetic ligands
11/25/2004	US20040236100 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
11/25/2004	US20040236098 Tocopheryl retinyl succinate, tocopheryl cholecalciferyl succinate or tocopheryl ascorbyl succinate; sustained releasing active agents or vitamin by hydrolyzing with esterase contained in the skin; dermatology, cosmetics
11/25/2004	US20040236095 formed by readcting chitosan with iminothiolane; improved viscoelasticity and gelation; for use in hair gels, eye drops, stents, and tissue engineering
11/25/2004	US20040236074 Antibacterial treatment of osteoarthritis
11/25/2004	US20040235965 Packaging ingredients for hearing disturbences from cardiovascular disorders and treatment with plant extracts from horse chestnuts
11/25/2004	US20040235964 Stable clear solution of sterile propofol solution in water
11/25/2004	US20040235962 Conformationally restricted polyamine analogs as disease therapies
11/25/2004	US20040235961 Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture
11/25/2004	US20040235960 Immunomodulation with novel pharmaceutical compositions
11/25/2004	US20040235958 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
11/25/2004	US20040235957 Use of sulfonamide derivatives as pharmaceuticals compounds
11/25/2004	US20040235956 Administration of carbetocin and/or other long-acting oxytocin analogs to inhibit initiation or growth of breast cancer and to treat, prevent or alleviate symptoms of psychiatric disorders such as obsessive-compulsive behavior; intranasal delivery
11/25/2004	US20040235955 Remedies for pruritus
11/25/2004	US20040235954 Method for treatment of premature ejaculation in humans
11/25/2004	US20040235952 Administering 6-Carbamoyl-4- {3-(4-fluoro-phenyl)-2-](-methoxy-1-H-indole-2-carbonyl)-amino]-propionylamino}-hex-2-enoic acid ethyl ester or other derivatives for inhibiting the activity of a coronavirus 3C protease
11/25/2004	US20040235951 Reacting an alkali metal salt of 3-methyl-4-oxocrotonic acid with a C15-triphenyl-phosphonium salt in presence of a base
11/25/2004	US20040235950 Administering, topically or systemically, an inhibitor of the matrix degrading enzymes and a cytokine inhibitor that alleviates inflammation and also alleviate neutrophil infiltration
11/25/2004	US20040235949 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
11/25/2004	US20040235948 Administering essential fatty acids with a high content of eicosapentaenoic acid ethyl ester (EPA) and/or docosahexaenoic acid ethyl ester (DHA) for preventing cardiovascular events in patients with diabetes mellitus
11/25/2004	US20040235947 Neuroprotective composition and uses thereof

1 ... 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 ... 7860